DOCSLIB.ORG

VIEWPOINTS Produced in Association with ACNR

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
VIEWPOINTS ���������������������������������������������������������������� Produced in Association with ACNR VIEWPOINTS Produced in association with ACNR Wednesday / Thursday / London Lecture – Friday / Expert-led 23 Refractory Epilepsy 24 what’s new in status epilepticus? 25 poster session Improving the treatment of refractory In The London Lecture, Professor Simon Highlights included the latest research epilepsy was a key focus of this meeting, Shorvon reviewed progress in our into SUDEP, hospitalisation rates, with topics ranging from dietary treatments, understanding of status epilepticus and AED use in clinical practice, and new to new surgical techniques and outcomes, highlighted some of the most promising data with eslicarbazepine acetate, and recent developments in AED treatment. new treatment approaches in development. perampanel, and other drug treatments. The 2015 Annual Scientific Meeting of the epilepticus (see page 6) and Professor Ingmar report of this well-attended symposium can be ILAE British Chapter, held in London on 23–25 Blümcke reviewing the latest analysis of surgical found on pages 4 and 5 of this newsletter. September 2015, brought together more than 300 outcomes in adults and children from the European We hope you enjoy this issue of VIEWPOINTS, epilepsy researchers and healthcare professionals Epilepsy Brain Bank (see page 2). Dr Jim Morrow which offers a selection of meeting highlights, and from across the British Isles. In a varied and from the Belfast Health and Social Care Trust was provides an update on some of the latest and most busy programme that included plenary sessions, awarded this year’s ILAE Excellence in Epilepsy exciting research underway across the country. sponsored satellite symposia, a debate, and an Award at the meeting and, in his award lecture, expert-led poster session, delegates heard news he presented encouraging new data on the risk of of the latest research from across the country in major congenital malformations associated with ILAE meetings give a chance a broad range of epilepsy topics. Opening the some of the newer antiepileptic drugs (AEDs) “ for all the groups in the epilepsy meeting, President of the ILAE British Chapter, (see page 3). community to come together, Dr John Paul Leach, described the annual event To mark the granting of a new indication in the UK including neurologists, nurses, as ‘one of my favourite meetings’, encouraging for the novel AED, perampanel (Fycompa®) as everyone to get involved in the discussions and psychologists, psychiatrists and an adjunctive treatment for primary generalised take an active part in the event. basic scientists. It is important tonic-clonic (PGTC) seizures in adults and that we all have a Several keynote presentations were made at the meeting by world-renowned epilepsy experts, generalised epilepsy (IGE), Eisai sponsored a broad outlook… with Professor Simon Shorvon delivering The satellite symposium entitled, ‘Do we need a new ” Dr John Paul Leach, London Lecture, focusing on what’s new in status therapeutic approach for our IGE patients?’. A President of the ILAE British Chapter Produced in association with Advances in Clinical Neuroscience & Rehabilitation (ACNR). Initiated and funded by Eisai Ltd. Prescribing information can be found on the last page. Epilepsy surgery continues to offer hope to patients with medically- Also new refractory epilepsy: new European and UK data presented at this Epilepsy surgery remains an important treatment Surgical outcomes data from 6899 adults and option for adults and children with medically- 2707 children were presented demonstrating refractory epilepsy, achieving seizure freedom in overall seizure-freedom rates at 12 months of meeting… many individuals. In the ILAE 2015 British Chapter 64.1% (Table 1). Rates were reported to be Annual International Lecture, Professor Ingmar similar in adults (74.0%) and children (65.1%). Walton Centre study suggests many patients Blümcke from the University Hospital Erlangen do not remain seizure-free in the long term in Germany presented the latest analysis of Table 1: 12-month seizure-freedom rates data from the European Epilepsy Brain Bank, reported in a recent (unpublished) analysis of A new study by The Walton Centre for to which three UK centres have contributed. data from the European Epilepsy Brain Bank Neurology and Neurosurgery and Liverpool University reported similarly good initial Onset of Age of outcomes of epilepsy surgery in 284 % patients Neuropathological spontaneous patients n (%) seizure-free at patients with medically-refractory epilepsy findings seizure activity at surgery 12 months (Wieshmann et al., 2015). In this study, a (years) (years) seizure freedom rate of 45% at 12 months Hippocampal sclerosis 3405 (35.4) 9 34 64.7 after surgery was reported, however, this Tumours 2189 (22.8) 13 25 71.3 reduced to 42% at 2 years, 29% at 5 years and 19% at 10 years post-surgery. In Malformations of 1873 (19.5) 3 15 63.5 cortical development his presentation to the meeting, Dr Udo Wieshmann from The Walton Centre said No lesions 739 (7.7) 11 28 51.7 that although surgery resulted in a dramatic Vascular malformation 564 (5.9) 21 35 65.8 reduction of seizures in many patients, long- Glial scars 473 (4.9) 8 25 52.0 term outcomes appeared less favourable. He proposed that surgery could potentially Dual pathology 223 (2.3) 6 28 61.3 convert a medically-refractory epilepsy to Encephalitis 135 (1.4) 5 12 60.4 a medically-treatable form and that better patient selection and new surgical techniques Double pathology 5 (0.1) 20 32 100 might improve outcomes in the future. Total 9606 12 28 64.1 According to Prof. Blümcke, the decision to operate tended to come sooner after seizure onset in Low complication rates reported by the children than in adults, with earlier surgery delivering better outcomes. He reported that epilepsy duration, localisation and histopathological diagnosis appeared to predict surgical outcomes, however, National Hospital for Neurology and he said, this had not yet been confirmed statistically due to the relatively small sample size. Neurosurgery A team from the National Hospital for Neurology Encouraging results with RTG RUF and Neurosurgery in London reported the ESL 2% the use of newer AEDs in 5% 2% results from a 25-year retrospective study of physical complications in 911 epilepsy a nurse-led community PER surgical procedures (Gooneratne et al., 17% epilepsy service ZNS 2015). Most (84%) procedures reviewed 48% were temporal lobe surgeries. No peri- LAC operative deaths were reported. A total of Newer AEDs are being used more frequently with 26% encouraging results, according to the findings of 131 (14%) of surgeries were complicated a recent audit of a nurse-led community epilepsy by persistent neurological complications; the service in mid-Staffordshire (Tittensor et al., 2015). most persistent anticipated complication was ESL, eslicarbazepine acetate; LAC, lacosamide; The audit included data from approximately 800 PER, perampanel; RTG, retigabine; RUF, ru!namide; a quadrantanopia (77 patients; 8%), which ZNS, zonisamide. patients under regular review by the service and occurred in 10% of patients who had temporal reported that 133 of these patients had been offered Figure 1: Percentage of treatment-refractory patients lobe surgery. Surgical complications occurred receiving one of the six newer AEDs (n=133) in a nurse-led treatment with one of the newer AEDs (Figure 1). community epilepsy service in mid-Staffordshire (Tittensor in 83 patients (9%). The group concluded Most patients trying these drugs had failed to have et al., 2015) that complication rates in their study were their epilepsy controlled with older medications. became seizure free in this study) despite being the similar to those reported in the literature and Zonisamide (n=63), lacosamide (n=35) and most treatment refractory (Tittensor et al., 2015). The that the risk of physical, neuropsychiatric and perampanel (n=22) were reported to have reduced research group from the Royal Wolverhampton NHS neuropsychological complications needed to seizure frequency by at least 50% in 62%, 76% and Trust and Keele University reported ‘encouraging be made clear to individuals considering this 65% of patients, respectively. Patients receiving statistics’ that, they concluded, supported the use treatment option. perampanel were most likely to achieve seizure of the newer AEDs in the treatment-refractory freedom of at least 6 months (18% of patients population being studied. 2 Produced in association with ACNR High rates of unscheduled admissions and readmissions in epilepsy cost the NHS millions al., 2015). A total of 177 1 year and one-third reattending five or more 350000 318768 admission episodes were times. The group called for further research to 300000 captured belonging to 120 characterise the clinical features of this cohort of 250000 200000 patients. These patients patients and to design alternative care pathways 146801 150000 were hospitalised for a total aimed at reducing costs and improving the quality 95758 100000 of 548 days and 13 patients of care. 39581 38666 35457 50000 28403 25576 24801 21039 7098 6445 6016 5232 4970 4506 4072 2483 2038 (10.8%) were admitted to Number of admissions 0 ITU. The length of disorders Ataxias h o s p i t a l i s a t i o n Meningitis Stroke or TIA Encephalitis Sleep disorders Multiple sclerosis ranged from 1 to 25 Cranial nerve disorders 25 Migraine and headaches Nervous system atrophy days (mean 4.55 Parkinson’s disease and dystonia Intracranial abscess or phlebitis Other disorders of nervous system Epilepsy including !t or seizure NOS Myopathies and myoneural disorders days) (Figure 3). Cerebral palsy and paralyticNerve syndromes root disorders and neuropathies Hydrocephalus and toxic encephalopathy Disorders of the autonomic nervous system Thirty-one patients 20 Alzheimer’s disease and other degenerative had a further 57 Figure 2: Neurological diagnoses ranked by number of emergency hospital r e a d m i s s i o n s 15 admissions between 31 April 2007 and 31 March 2013 (Hick et al., 2015) (Figure 4) – the Percent High rates of unscheduled admissions for adults majority due to 10 with suspected seizures are costing the NHS uncontrolled epilepsy.
Load more

Recommended publications
  • A Drug Repositioning Approach Identifies Tricyclic Antidepressants As Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors
    Published OnlineFirst September 26, 2013; DOI: 10.1158/2159-8290.CD-13-0183 RESEARCH ARTICLE A Drug Repositioning Approach Identifi es Tricyclic Antidepressants as Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors Nadine S. Jahchan 1 , 2 , Joel T. Dudley 1 , Pawel K. Mazur 1 , 2 , Natasha Flores 1 , 2 , Dian Yang 1 , 2 , Alec Palmerton 1 , 2 , Anne-Flore Zmoos 1 , 2 , Dedeepya Vaka 1 , 2 , Kim Q.T. Tran 1 , 2 , Margaret Zhou 1 , 2 , Karolina Krasinska 3 , Jonathan W. Riess 4 , Joel W. Neal 5 , Purvesh Khatri 1 , 2 , Kwon S. Park 1 , 2 , Atul J. Butte 1 , 2 , and Julien Sage 1 , 2 Downloaded from cancerdiscovery.aacrjournals.org on September 29, 2021. © 2013 American Association for Cancer Research. Published OnlineFirst September 26, 2013; DOI: 10.1158/2159-8290.CD-13-0183 ABSTRACT Small cell lung cancer (SCLC) is an aggressive neuroendocrine subtype of lung cancer with high mortality. We used a systematic drug repositioning bioinformat- ics approach querying a large compendium of gene expression profi les to identify candidate U.S. Food and Drug Administration (FDA)–approved drugs to treat SCLC. We found that tricyclic antidepressants and related molecules potently induce apoptosis in both chemonaïve and chemoresistant SCLC cells in culture, in mouse and human SCLC tumors transplanted into immunocompromised mice, and in endog- enous tumors from a mouse model for human SCLC. The candidate drugs activate stress pathways and induce cell death in SCLC cells, at least in part by disrupting autocrine survival signals involving neurotransmitters and their G protein–coupled receptors. The candidate drugs inhibit the growth of other neuroendocrine tumors, including pancreatic neuroendocrine tumors and Merkel cell carcinoma.
    [Show full text]
  • Comparison of Electropharmacological Effects of Bepridil and Sotalol in Halothane-Anesthetized Dogs
    Circ J 2008; 72: 1003–1011 Comparison of Electropharmacological Effects of Bepridil and Sotalol in Halothane-Anesthetized Dogs Tomomichi Ishizaka, DVM*,**; Akira Takahara, PhD*; Hiroshi Iwasaki, MD*; Yoshitaka Mitsumori, MD*; Hiroaki Kise, MD*; Yuji Nakamura, MS*; Atsushi Sugiyama, MD*,** Background Bepridil is known to have a multiple ion channel-blocking property in the heart, which has been applied for the treatment of atrial fibrillation and drug-refractory ventricular tachyarrhythmias. In this study, the electro-pharmacological effects of bepridil were compared with those of dl-sotalol, a representative class III anti- arrhythmic drug, using the halothane-anesthetized canine model. Methods and Results Cardiovascular and electrophysiological variables were measured under the halothane anesthesia. Intravenous administration of bepridil (0.3mg/kg, n=4) delayed the intraventricular conduction and prolonged the ventricular effective refractory period, whereas dl-sotalol (0.3mg/kg, iv, n=4) inhibited atrioven- tricular conduction and prolonged the atrial and ventricular effective refractory period. The additional adminis- tration of 10 times the higher dose of bepridil or dl-sotalol (ie, 3mg/kg, iv, n=4 for each group) decreased blood pressure, suppressed ventricular contraction and sinus automaticity, and prolonged the atrial and ventricular effective refractory period and monophasic action potential duration, in addition to the effects of the low dose. Conclusions The electropharmacological effects of bepridil and dl-sotalol were similar,
    [Show full text]
  • Evaluation and Management of Chronic Hepatitis C Virus Infection
    EVALUATION AND MANAGEMENT OF CHRONIC HEPATITIS C VIRUS (HCV) INFECTION Federal Bureau of Prisons Clinical Guidance MAY 2017 Federal Bureau of Prisons (BOP) Clinical Guidance is made available to the public for informational purposes only. The BOP does not warrant this guidance for any other purpose, and assumes no responsibility for any injury or damage resulting from the reliance thereof. Proper medical practice necessitates that all cases are evaluated on an individual basis and that treatment decisions are patient- specific. Consult the BOP Health Management Resources Web page to determine the date of the most recent update to this document: http://www.bop.gov/resources/health_care_mngmt.jsp. Federal Bureau of Prisons Evaluation and Management of Chronic HCV Infection Clinical Guidance May 2017 WHAT’S NEW IN BOP GUIDANCE REGARDING HCV INFECTION? The major changes included in this May 2017 update to the BOP guidance on chronic HCV infection are based primarily on the April 2017 changes to the American Association for the Study of Liver Diseases (AASLD) guidelines, as follows: • The term resistance-associated substitutions (RASs) is now being used instead of resistance- associated variants (RAVs). • Anti-HBs and anti-HBc, in addition to HBsAg, are recommended for baseline testing of hepatitis B status (see LABORATORY TESTS under BASELINE EVALUATION). • Ledipasvir/sofosbuvir once daily for eight weeks is now an AASLD-recommended regimen for treatment in a subgroup of HCV-infected persons who have genotype 1a or 1b, have an HCV viral load <6 million IU/ml, and are treatment-naïve—but who are not black, are not HIV-coinfected, and do not have cirrhosis.
    [Show full text]
  • Comparison of In-Cell Immunoassay and Automated Electrophysiology for Assessment of Herg Trafficking Liability for New Drugs
    Comparison of in-cell immunoassay and automated electrophysiology for assessment of hERG trafficking liability for new drugs Yuri Kuryshev, Peter Hawryluk, Caiyun Wu, Abby Sewell, James Kramer, Carlos Obejero-Paz, Luke Armstrong, Arthur M. Brown Charles River, Cleveland, Ohio, USA IWB/PPC 1 h IWB/PPC 24 h 1.8 1.8 hERG-Lite 16 h hERG-Lite 1 h 1 3 1.6 Abstract Results 1.6 4 Summary 1.4 1.4 hERG-Lite® is an antibody-based chemiluminescent assay that identifies compounds that disrupt Voltage clamp population patch: functional assay for 1.2 1.2 trafficking or suppress expression of hERG channel protein. Electrophysiological recording from measuring relative changes in membrane surface hERG 1.0 1.0 hERG-Lite® : in-cell immunoassay for measuring relative single cell using the manual patch-clamp technique is more direct way to quantify hERG expression in 0.8 0.8 0.6 0.6 cell membrane but this method has critical limitations: low throughput and selection bias during choice channelAa levels Ab Vehicle Control Pentamidine changes in hERG channel surface levels 24 hr. 1 hr. 0.4 0.4 Fraction of Control Fraction of Control of cells for patching. Application of the automated population patch clamp technique for the hERG 1hr. 30 M/1 hr. 30 M 30 M 0.2 0.2 VC Pent. VC Pent. expression analysis provides a dramatic increase in throughput and eliminates the cell selection bias. 0.0 0.0 hERG-Lite WB* IWB/PPC We analyzed a panel of drugs (Amiodarone, Amitriptyline, Bepridil, Diphenhydramine, Dofetilide, 0.03 0.1 0.3 1 0.03 0.1 0.3 1 Amiodarone ↓ ↓ N.D.** Fluoxetine, Imipramine, Ouabaine, Pentamidine, Pimozide, Sunitinib and Verapamil) for chronic effects Pimozide, M Pimozide, M Amitriptyline ↓ ↓ ↓ on hERG channel trafficking and expression by the hERG-Lite® method and with IonWorks Barracuda IWB/PPC 1 h IWB/PPC 24 h hERG-Lite 1 h hERG-Lite 16 h (IWB), a population-based automated patch clamp platform.
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • Evaluation of Ruxolitinib and Pracinostat Combination As a Therapy for Patients with Myelofibrosis 2014-0445
    2014-0445 October 23, 2016 Page 1 Protocol Page EVALUATION OF RUXOLITINIB AND PRACINOSTAT COMBINATION AS A THERAPY FOR PATIENTS WITH MYELOFIBROSIS 2014-0445 Core Protocol Information Short Title Ruxolitinib and Pracinostat Combination Therapy for Patients with MF Study Chair: Srdan Verstovsek Additional Contact: Paula J. Cooley Sandra L. Rood Leukemia Protocol Review Group Department: Leukemia Phone: 713-792-7305 Unit: 428 Full Title: EVALUATION OF RUXOLITINIB AND PRACINOSTAT COMBINATION AS A THERAPY FOR PATIENTS WITH MYELOFIBROSIS Protocol Type: Standard Protocol Protocol Phase: Phase II Version Status: Terminated 06/01/2018 Version: 13 Submitted by: Sandra L. Rood--10/23/2017 2:12:37 PM OPR Action: Accepted by: Elizabeth Orozco -- 10/26/2017 1:34:18 PM Which Committee will review this protocol? The Clinical Research Committee - (CRC) 2014-0445 October 23, 2016 Page 2 Protocol Body EVALUATION OF RUXOLITINIB AND PRACINOSTAT COMBINATION AS A THERAPY FOR PATIENTS WITH MYELOFIBROSIS 1.0 HYPOTHESIS AND OBJECTIVES Hypothesis Ruxolitinib (also known as INCB018424), a JAK1/2 inhibitor, and pracinostat (a histone deacetylase inhibitor; HDACi) are effective and tolerable treatments for patients with myelofibrosis (MF). Combination of these agents in patients with MF can improve the overall clinical response to therapy without causing excessive toxicity. Objectives Primary: to determine the efficacy/clinical activity of the combination of ruxolitinib with pracinostat as therapy in patients with MF Secondary: to determine the toxicity of the combination of ruxolitinib with pracinostat as therapy in patients with MF Exploratory: to explore time to response and duration of response to explore changes in bone marrow fibrosis to explore changes in JAK2V617F (or other molecular marker) allele burden or changes in cytogenetic abnormalities 2.0 BACKGROUND AND RATIONALE 2.1 Myelofibrosis Myelofibrosis (MF) is a rare clonal proliferative disorder of a pluripotent stem cell.
    [Show full text]
  • Neuroleptics of the Diphenylbutylpiperidine Series Are Potent Calcium Channel Inhibitors
    Proc. Nati. Acad. Sci. USA Vol. 83, pp. 7513-7517, October 1986 Neurobiology Neuroleptics of the diphenylbutylpiperidine series are potent calcium channel inhibitors (fluspirilene/desmethoxverapamil/binding/voltage-clamp/skeletal muscle) JEAN-PIERRE GALIZZI, MICHEL FOSSET, GEORGES ROMEY, PIERRE LADURON*, AND MICHEL LAZDUNSKI Centre de Biochimie du Centre National de la Recherche Scientifique, Parc Valrose, 06034 Nice Cedex, France Communicated by Jean-Marie Lehn, June 5, 1986 ABSTRACT [1t4]Fluspirilene, a neuroleptic molecule of spirilene and directly demonstrate that molecules in the the diphenylbutylpiperidine series, binds to skeletal muscle DPBP series are among the most potent inhibitors of the transverse tubule membranes with a high affinity correspond- skeletal muscle Ca2+ channel. ing to a Kd of 0.11 * 0.04 nM. A 1:1 stoichiometry was found between [3H]fluspirilene binding and the binding of (-)- [3H]desmethoxyverapamil {(-)[3H]D888}, one of the most MATERIALS AND METHODS potent Ca2+ channel inhibitors. Ca2+ channel inhibitors such as D888, verapamil, gallopamil, bepridil, or diltiazem antag- Materials. (-)[3H]D888 (82 Ci/mmol; 1 Ci = 37 GBq) and onize [3H]fluspirilene binding besides antagonizing (-)[3H]- the 1,4-dihydropyridine (+)[3H]PN 200-110 (80 Ci/mmol) D888 binding. Neuroleptics, especially those of the diphenyl- were obtained from Amersham; (-)D888, verapamil, and butylpiperidine family, also antagonize both (-)[3H]D888 gallopamil were from Knoll AG (Ludwigshafen, F.R.G.); binding and [3H]fluspirilene binding. There is an excellent bepridil and the bepridil analogs 4205 {1-[(1-propynyl)- correlation between affinities found from [3H~fluspirilene bind- cyclohexyloxy]-2-(1-pyrrolidinyl)-3-[(2-methyl)propoxyjpro- ing experiments and those found from (-)[3H]D888 binding pane chlorhydrate} and 11787 [N-(4-chloro)phenylmethyl-N- experiments.
    [Show full text]
  • ( 12 ) United States Patent
    US010117881B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 , 117 ,881 B2 Helson (45 ) Date of Patent: * Nov. 6 , 2018 ( 54 ) PROTECTIVE EFFECT OF DMPC , DMPG , (58 ) Field of Classification Search DMPC /DMPG , LYSOPG AND LYSOPC None AGAINST DRUGS THAT CAUSE See application file for complete search history . CHANNELOPATHIES (71 ) Applicant: SignPath Pharma Inc. , Quakertown , ( 56 ) References Cited PA ( US) U . S . PATENT DOCUMENTS (72 ) Inventor: Lawrence Helson , Quakertown , PA 4 , 812 , 312 A 3 / 1989 Lopez -Berestein et al . (US ) 5 ,023 ,087 A 6 / 1991 Yau - Young 5 ,679 ,864 A 10 / 1997 Krackov et al . ( 73 ) Assignee : Signpath Pharma, Inc. , Sandy, UT 6 , 143 , 276 A 11/ 2000 Unger (US ) 6 , 787 , 132 B1 9 /2004 Gabison et al . 6 , 946 ,475 B1 9 / 2005 Lloyd ( * ) Notice : Subject to any disclaimer, the term of this 7 ,060 ,733 B2 6 / 2006 Pandol et al . patent is extended or adjusted under 35 7 , 067 , 159 B2 6 / 2006 Katz et al. U . S . C . 154 ( b ) by 0 days. 7 , 507 , 864 B2 3 / 2009 Miller et al. 7 ,674 , 820 B2 3 / 2010 Fedida et al. This patent is subject to a terminal dis 7 , 723 , 515 B1 5 / 2010 DiMauro claimer. 7 ,871 ,609 B2 1 / 2011 Ziff et al . 7 , 968, 115 B26 / 2011 Kurzrock et al . 8 , 062 ,663 B2 11/ 2011 Wang et al. ( 21) Appl . No. : 15 /347 , 381 8 , 153 , 172 B2 4 / 2012 Antony 8 , 202, 839 B1 6 / 2012 Sung (22 ) Filed : Nov . 9 , 2016 8 , 207 ,219 B2 6 / 2012 Fedida et al .
    [Show full text]
  • Prescription Medications, Drugs, Herbs & Chemicals Associated With
    Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus American Tinnitus Association Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form, or by any means, without the prior written permission of the American Tinnitus Association. ©2013 American Tinnitus Association Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus American Tinnitus Association This document is to be utilized as a conversation tool with your health care provider and is by no means a “complete” listing. Anyone reading this list of ototoxic drugs is strongly advised NOT to discontinue taking any prescribed medication without first contacting the prescribing physician. Just because a drug is listed does not mean that you will automatically get tinnitus, or exacerbate exisiting tinnitus, if you take it. A few will, but many will not. Whether or not you eperience tinnitus after taking one of the listed drugs or herbals, or after being exposed to one of the listed chemicals, depends on many factors ‐ such as your own body chemistry, your sensitivity to drugs, the dose you take, or the length of time you take the drug. It is important to note that there may be drugs NOT listed here that could still cause tinnitus. Although this list is one of the most complete listings of drugs associated with tinnitus, no list of this kind can ever be totally complete – therefore use it as a guide and resource, but do not take it as the final word. The drug brand name is italicized and is followed by the generic drug name in bold.
    [Show full text]
  • Medications to Avoid in Long QT Syndrome
    Jackie Crawford Cardiac Inherited Disease Co-ordinator C/- Paediatric Cardiology; Level 3 Starship; Auckland City Hospital Private Bag 92024; Auckland Cardiac Inherited Disease Registry Phone: (09) 3074949 ext 23634 www.cidg.org Fax: (09) 6309877 Email: [email protected] Medications to be avoided, or requiring special caution, in people with Long QT syndrome This list includes medications which prolong the QT interval and is meant as a guide for people with Long QT syndrome, or acquired long QT interval from heart muscle disease, and their parents or guardians. It should not be seen as all inclusive. Those prescribing any medication to someone with Long QT syndrome should always check the drug specifications and contra-indications. The list has been compiled by review of publications and/or drug advice sheets provided with medications. Check also www.SADS.org and www.Torsades .org. Antibiotics Erythromycin, Clarithromycin, Gatifloxacin, levofloxacin, Moxifloxacin Sulfamethoxazole-trimethoprim (Septrin/Bactrim), Spiramycin, Pentamidine Antihistamines Terfenadine, Astemizole, Diphenhydramine, (These are particularly to be avoided (even in normal subjects) in combination with Erythromycin or grapefruit juice or the antifungals ketoconazole, miconazole, fluconazole or itraconazole) [Antihistamines that may be used safely are loratidine, cetirizine and fexofenadine, and phenergan] Appetite suppressants Fenfluramine, phentermine, Sibutramine Asthma treatments The Beta-2 agonists (e.g. Terbutaline, Salbutamol, Salmeterol) both work against
    [Show full text]
  • Johansen 1..13
    RESEARCH ARTICLE EBOLA VIRUS A screen of approved drugs and molecular probes identifies therapeutics with anti–Ebola virus activity Lisa M. Johansen,1 Lisa Evans DeWald,2 Charles J. Shoemaker,3 Benjamin G. Hoffstrom,1 Calli M. Lear-Rooney,2 Andrea Stossel,2 Elizabeth Nelson,3 Sue E. Delos,3 James A. Simmons,3 Jill M. Grenier,1 Laura T. Pierce,1 Hassan Pajouhesh,1 Joseph Lehár,1,4 Lisa E. Hensley,2 Pamela J. Glass,2 Judith M. White,3 Gene G. Olinger2*† Currently, no approved therapeutics exist to treat or prevent infections induced by Ebola viruses, and recent events have demonstrated an urgent need for rapid discovery of new treatments. Repurposing approved drugs for emerging infections remains a critical resource for potential antiviral therapies. We tested ~2600 approved drugs and molecular probes in an in vitro infection assay using the type species, Zaire ebolavirus. Selective antiviral activity was found for 80 U.S. Food and Drug Administration–approved drugs spanning multiple mech- anistic classes, including selective estrogen receptor modulators, antihistamines, calcium channel blockers, and antidepressants. Results using an in vivo murine Ebola virus infection model confirmed the protective ability of several drugs, such as bepridil and sertraline. Viral entry assays indicated that most of these antiviral drugs block a late stage of viral entry. By nature of their approved status, these drugs have the potential to be rapidly advanced to clinical settings and used as therapeutic countermeasures for Ebola virus infections. INTRODUCTION as well as drugs acting through mechanisms that would not have been Filoviruses (Ebolavirus and Marburgvirus) are responsible for acute vi- predicted (11).
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]